AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03079388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
Study NCT03079388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Single dose albendazole 400mg given in the second trimester.
Study NCT03079388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Single dose albendazole 400mg given in the second trimester.
Study NCT03079388 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis testing and treatment
Description: Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
Study NCT00520832 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Microcurrent
Description: Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
Study NCT00754468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Spray Ablation
Description: Cryo Spray Ablation 4 cycles x 10 seconds treatment
Study NCT00754468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Spray Ablation
Description: Cryo Spray Ablation 2 cycles x 20 seconds
Study NCT00136123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of functional loaded synthetic teeth after placement implants
Description: Placement of functional loaded synthetic teeth after placement implants
Study NCT01349231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Ketamine (a single 0.5mg intravenously over 40 minutes).
Study NCT01988220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory retraining
Study NCT01988220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repeated sensory input
Description: sensory stimulation without attentive learning focus
Study NCT02424448 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsies, blood and urine samples
Description: Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken.
Study NCT02922855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 0 dollars group
Description: Those assigned to the $0 group will not receive an incentive for visiting their PCP.
Study NCT02922855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50 dollars group
Description: Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
Study NCT02922855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 25 dollars group
Description: Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
Study NCT01624337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-piperaquine
Description: Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)
Study NCT03217526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
Study NCT03217526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait Training
Description: Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
Study NCT03827473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03756974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX-1
Description: BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
Study NCT03756974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of BX-1, oral solution
Study NCT03643432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise adherence intervention
Description: Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
Study NCT02931396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Study NCT03643432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
Study NCT02666092 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
Study NCT02666092 — intervention group
Intervention type: BIOLOGICAL
Intervention: Detection of anti-Anisakis and anti-fish antibodies
Description: Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
Study NCT02908958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
Study NCT02908958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
Study NCT00595699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
Study NCT00595699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT02075762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial biopsy
Study NCT02075762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprobe biopsy
Study NCT02075762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS biopsy
Study NCT02179515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-brachyury- TRICOM
Description: It is an active cancer immunotherapy administered via subcutaneous injection.
Study NCT01798134 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TANDEM™
Study NCT02259413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Rehabilitation
Description: This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
Study NCT02288767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional arterial blood pressure monitoring
Study NCT02288767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke volume variation monitoring with arterial blood pressure monitoring
Study NCT03532945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioactive Glass-Ceramic Spacer
Study NCT00497588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT03532945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium cage
Study NCT01151995 — intervention group
Intervention type: OTHER
Intervention: Remote source document verification
Description: Remote access to electronic medical records of the 5 participating sites
Study NCT01151995 — intervention group
Intervention type: OTHER
Intervention: On-site source document verification
Description: Study monitor will perform on-site source document verification during routine visit to the five participating sites
Study NCT04302610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,
Description: A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments
Study NCT04302610 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
Study NCT04591912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mind. body. voice
Description: The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
Study NCT04762108 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Patients will be given standard of care as per their clinical needs
Study NCT03073655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Verbal Input
Description: The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
Study NCT03073655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral Verbal Input
Description: The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
Study NCT03073655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Verbal Input
Description: The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
Study NCT00497588 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Study NCT00828919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
Study NCT00828919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
Study NCT02413528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
Study NCT02413528 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
Study NCT02413528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application for asthma adherence
Description: Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
Study NCT03394716 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: standard radiotherapy treatment with 1-3 extra MRIs
Study NCT04402606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation on skin toxicities
Description: Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
Study NCT02465359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous (Human)
Description: Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
Study NCT02516774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study NCT04774224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
Study NCT04774224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
Study NCT01624337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00914485 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider Communication Skills Training
Description: Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity.
Study NCT04344158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105 Injection
Description: AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
Study NCT01273480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
Study NCT01273480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
Study NCT04344158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Study NCT04344158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib Tosylate Tablets
Description: Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
Study NCT00952224 — intervention group
Intervention type: OTHER
Intervention: magnetic resonance imaging
Description: magnetic resonance imaging is used for prognosis assessment
Study NCT04066413 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula
Description: Standard infant formula
Study NCT04066413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula supplemented with HMO
Description: Infant formula supplemented with HMO
Study NCT00458289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum carbonate (chewed vs. crushed)
Description: single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
Study NCT01287715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
Study NCT01287715 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: etanercept
Description: Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
Study NCT03876028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Infusion
Study NCT03876028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral (tablets or capsules)
Study NCT00987025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Use of telehealth blood pressure station every week
Study NCT00987025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Control
Study NCT02824887 — intervention group
Intervention type: OTHER
Intervention: Electro-acupuncture
Description: Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
Study NCT02824887 — intervention group
Intervention type: OTHER
Intervention: Conventional treatment of Western Medicine
Description: Routine non operative treatment of Western Medicine
Study NCT03996616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Head UP Position
Description: CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a \<10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput.
Study NCT03996616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impedance Threshold Device
Description: An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
Study NCT03996616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Automated CPR
Description: Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
Study NCT00549341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin
Description: 100U vials, doses ranged from 50U-200U, single injection.
Study NCT00549341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Single injection.
Study NCT06613815 — intervention group
Intervention type: OTHER
Intervention: radiofrequency of the geniculate nerves
Description: radiofrequency of the geniculate nerveswith a scopy-guided technique versus the ultrasound-guided technique
Study NCT00076245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Light therapy will involve exposure to bright light twice a day.
Study NCT00076245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
Study NCT05188924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-306
Description: Active ingredients
Study NCT05188924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02400515 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: This is a quasi-experimental study and the same group was evaluated before and after the exercise.
Study NCT04523246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)
Description: The Shingrix vaccine is a subunit vaccine that contains the recombinant varicella zoster virus (VZV) glycoprotein E (gE), adjuvanted with the proprietary Adjuvant System (AS01B). The AS01B Adjuvant system consists of two immune-stimulants, the saponin, Quillaja saponaria Molina, fraction 21 (QS21), and the toll-like receptor 4 (TLR4) agonist, MPL (3-O-desacyl-40-MPL) that enhance the release of interferon gamma (IFNϒ), which in turn stimulates activation and recruitment of blood monocyte-derived and resident lymph node dendritic cells to take up and present gE to cluster of differentiation 4 (CD4+) T cells.
Study NCT04523246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile normal saline, inactive control.
Study NCT01325506 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire, telephone interviews, and clinical follow-up